Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Archives of Dermatological Research

• Publication date

  1995-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01262331PMID 7763091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antihistone antibodies in patients with localized scleroderma.

  1993cited by this paper
• Clinical evaluation of scleroderma spectrum disorders using a points system

  1992cited by this paper
• Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.

  1992cited by this paper
• Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4.

  1992cited by this paper
• Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.

  1992cited by this paper
• Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

  1991cited by this paper
• Soluble immunologic products in scleroderma sera.

  1991cited by this paper
• IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils.

  1990cited by this paper
• Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

  1990cited by this paper
• Soluble interleukin‐2 receptor, interleukin‐2 and interleukin‐4 in sera and supernatants from patients with progressive systemic sclerosis

  1990cited by this paper
• Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.

  1990cited by this paper
• Anti-single-stranded DNA antibody and muscle involvement in localized scleroderma.

  1990cited by this paper
• The biology of interleukin-6.

  1989cited by this paper
• Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

  1989cited by this paper
• Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration.

  1989cited by this paper
• Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones.

  1988cited by this paper
• Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T cells?

  1988cited by this paper
• Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6).

  1988cited by this paper
• Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.

  1988cited by this paper
• Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis

  1988cited by this paper
• Molecular Biology of Interleukin 4 and Interleukin 5 Genes and Biology of their Products that Stimulate B Cells, T Cells and Hemopoietic Cells

  1988cited by this paper
• Restricted production of interleukin 4 by activated human T cells.

  1988cited by this paper
• Genes coding for RNA polymerase β subunit in bacteria

  1988cited by this paper
• Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.

  1988cited by this paper
• B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells.

  1987cited by this paper
• Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities.

  1986cited by this paper
• Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation.

  1986cited by this paper
• Antinuclear antibodies in the relatives of patients with systemic sclerosis

  1985cited by this paper
• Pathophysiologic aspects of lymphokines.

  1985cited by this paper
• Juvenile linear scleroderma associated with serologic abnormalities.

  1985cited by this paper
• Interleukin 2.

  1984cited by this paper
• Antinuclear antibodies in localized scleroderma.

  1983cited by this paper
• Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

  1982cited by this paper
• Identification of a T cell-derived b cell growth factor distinct from interleukin 2

  1982cited by this paper
• When is scleroderma not scleroderma? The differential diagnosis of progressive systemic sclerosis.

  1981cited by this paper
• When is scleroderma not scleroderma? The differential diagnosis of progressive systemic sclerosis.

  1981cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma).

  1980cited by this paper
• Growth and Development of Rheumatology in the United States—A Bicentennial Report

  1977cited by this paper
• Functional and morphologic characterization of human T cells continuously grown in vitro.

  1977cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper
• Proceedings: Serologic abnormalities and their significance in localized scleroderma.

  1975cited by this paper
• Proceedings: Serologic abnormalities and their significance in localized scleroderma.

  1975cited by this paper
• The cutaneous collagenoses.

  1973cited by this paper
• Generalized morphea. I. Histology of the dermis and subcutaneous tissue.

  1972cited by this paper
• Systemic scleroderma.

  1970cited by this paper
• Systemic scleroderma, A clinical study of 727 cases.

  1961cited by this paper

• Is adiponectin involved in morphea pathogenesis? – first observational study

  2025cites this paper
• Autologous Fibroblast Cells in Platelet‐Rich Plasma Injection as a Novel Treatment for Inactive En Coup de Sabre Deformity

  2025cites this paper
• Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?

  2024cites this paper
• Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma

  2024cites this paper
• Morphea: The 2023 update

  2023influential citation
• IL-6 trans-signaling in a humanized mouse model of scleroderma

  2023cites this paper
• Unravelling morphoea aetiopathogenesis by next-generation sequencing of paired skin biopsies

  2023cites this paper
• Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma

  2022cites this paper
• Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea

  2022cites this paper
• Fractional Ablative Carbon Dioxide Lasers for the Treatment of Morphea: A Case Series and Literature Review

  2022cites this paper
• Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial

  2022cites this paper
• Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?

  2022cites this paper
• Immunologic underpinnings and treatment of morphea

  2022influential citation
• Association of Serum IL 6 with Different Clinical Presentations of Systemic Sclerosis Patients: A Case-Control Study

  2021cites this paper
• Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review

  2021cites this paper
• Novel role of long non-coding RNAs in autoimmune cutaneous disease.

  2021cites this paper
• Genetic Signatures From RNA Sequencing of Pediatric Localized Scleroderma Skin

  2021cites this paper
• Morphea: progress to date and the road ahead

  2021cites this paper
• Transcriptomic Evaluation of Juvenile Localized Scleroderma Skin With Histologic and Clinical Correlation

  2021cites this paper
• Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts

  2021cites this paper
• Hypopigmentary Skin Disorders

  2021cites this paper
• Clinical characteristics and histopathological changes of morphea: A single-center, retrospective study of 137 patients.

  2020cites this paper
• Juvenile Localized Scleroderma. Questions of Treatment

  2020cites this paper
• Update on the Systemic Treatment of Pediatric Localized Scleroderma

  2019cites this paper
• Immunopathogenesis of Juvenile Systemic Sclerosis

  2019cites this paper
• Immunopathogenesis of Pediatric Localized Scleroderma

  2019influential citation
• Morphoea (Localized Scleroderma)

  2019cites this paper
• The efficacy of methotrexate in the treatment of en coup de sabre (linear morphea subtype)

  2018cites this paper
• The molecular pathogenesis of morphoea: from genetics to future treatment targets

  2017cites this paper
• European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

  2017cites this paper
• Interleukin-6 and Related Proteins as Biomarkers in Systemic Sclerosis

  2017cites this paper
• Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis

  2017cites this paper
• Chapter 108 – Pediatric Systemic Lupus Erythematosus, Juvenile Dermatomyositis, Scleroderma, and Vasculitis

  2017cites this paper
• Morphea (localized scleroderma)

  2017cites this paper
• Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.

  2017cites this paper
• Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma

  2016cites this paper
• Localized scleroderma: a review

  2016cites this paper
• Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy

  2015cites this paper
• 147 – Localized scleroderma and scleroderma-like syndromes

  2015cites this paper
• Autoimmune skin diseases: Role of sex hormones, vitamin d, and menopause

  2015cites this paper
• Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

  2015cites this paper
• Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients

  2014cites this paper
• Biologics in systemic sclerosis.

  2014cites this paper
• Interleukin-6 (IL-6) Trans Signaling Drives a STAT3-dependent Pathway That Leads to Hyperactive Transforming Growth Factor-β (TGF-β) Signaling Promoting SMAD3 Activation and Fibrosis via Gremlin Protein

  2014cites this paper
• IL-6 trans signalling drives a STAT3 dependant pathway that leads to hyperactive TGF-β signalling promoting SMAD3 activation and fibrosis via gremlin

  2013cites this paper
• Epithelial–mesenchymal transition of the eccrine glands is involved in skin fibrosis in morphea

  2013cites this paper
• Updates on Morphea: Role of Vascular Injury and Advances in Treatment

  2013cites this paper
• Autoimmunity Diseases of the Skin

  2013cites this paper
• Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.

  2013cites this paper
• Pediatric Scleroderma –Systemic and Localized Forms

  2012cites this paper
• Pediatric scleroderma: systemic or localized forms.

  2012cites this paper
• Methotrexate and Corticosteroids in the Treatment of Localized Scleroderma: A Standardized Prospective Longitudinal Single-center Study

  2012cites this paper
• Morphea and other localized forms of scleroderma

  2012cites this paper
• Fibrosis: Insights from the Stiff Skin Syndrome

  2012cites this paper
• Localized scleroderma

  2012cites this paper
• Morphea associated with the use of adalimumab: a case report and review of the literature

  2012cites this paper
• Localized Forms of Scleroderma

  2012cites this paper
• Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma.

  2011cites this paper
• Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial.

  2011cites this paper
• Cytokine profiles in localized scleroderma and relationship to clinical features.

  2011influential citation
• Chapter 26 – LOCALIZED SCLERODERMAS

  2011cites this paper
• Morphoea (Localized Scleroderma)

  2011cites this paper
• Abstract and Introduction

  2010cites this paper
• Localized scleroderma and zinc: a pilot study.

  2010cites this paper
• Animal models of scleroderma: fresh insights

  2010cites this paper
• Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension.

  2009cites this paper
• Effectiveness, side‐effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study

  2009cites this paper
• Efficacy of Topical Tacrolimus 0.1% in Active Plaque Morphea

  2009cites this paper
• Diagnosis and Therapy of Localized Scleroderma

  2009cites this paper
• Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus.

  2009cites this paper
• Diagnosis and Therapy of Localized Scleroderma

  2009cites this paper
• AWMF‐Leitlinie Nr. 013/066 Diagnostik und Therapie der zirkumskripten Sklerodermie

  2009cites this paper
• Altered adhesion molecules expression on peripheral blood mononuclear cells from patients with systemic sclerosis and clinical correlations

  2009cites this paper
• Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma

  2009cites this paper
• Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.

  2008cites this paper
• Disabling pansclerotic morphea of childhood – unusual case and management challenges

  2008cites this paper
• Native human IFN-alpha is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-alpha.

  2007cites this paper
• Native Human IFN-α Is a More Potent Suppressor of HDF Response to Profibrotic Stimuli Than Recombinant Human IFN-α

  2007cites this paper
• Antihistone antibodies in linear scleroderma variants

  2006cites this paper
• Role of Th1 and Th2 Cells in Autoimmunity

  2006cites this paper
• Ultraviolet A1‐induced downregulation of human β‐defensins and interleukin‐6 and interleukin‐8 correlates with clinical improvement in localized scleroderma

  2006cites this paper
• Elevated whole blood chemiluminescence in patients with systemic sclerosis.

  2005cites this paper
• Rheumatoid factor isotypes in localized scleroderma

  2005cites this paper
• Localized scleroderma is an autoimmune disorder.

  2005cites this paper
• Anti‐agalactosyl immunoglobulin G antibodies in localized scleroderma

  2005cites this paper
• Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma.

  2005cites this paper
• Serum levels of manganese superoxide dismutase in patients with localized scleroderma

  2004cites this paper
• Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes.

  2004cites this paper
• Serum Cytokines in Metastatic Melanoma Patients Treated with an Autologous Tumor Vaccine

  2003cites this paper
• Serum Levels of Tumor Necrosis Factor and Interleukin-13 Are Elevated in Patients with Localized Scleroderma

  2003cites this paper
• Scleroderma in children and adolescents.

  2002cites this paper
• Anti-U1RNP antibodies in patients with localized scleroderma

  2001cites this paper
• Interleukin-6 promoter polymorphism (--174 G/C) in Caucasian German patients with systemic lupus erythematosus.

  2001cites this paper
• Localized and systemic scleroderma show different histological responses to methotrexate therapy

  2001cites this paper
• Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis.

  2001cites this paper
• From the Simple Detection of Microchimerism in Patients with Autoimmune Diseases to Its Implication in Pathogenesis

  2001cites this paper
• Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.

  2000cites this paper
• Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma.

  2000cites this paper
• Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin).

  2000cites this paper
• Methotrexate and corticosteroid therapy for pediatric localized scleroderma.

  2000cites this paper